Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Trial ID or NCT#
Status
Purpose
Omidubicel is an investigational therapy for patients with high-risk hematologic malignancies.
Official Title
An Open Label Expanded Access Study of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies
Eligibility Criteria
- - Patients must be at least 12 years of age - Applicable disease criteria - Patients must have one or two partially HLA-matched CBUs - Back-up stem cell source - Sufficient physiological reserves - Females of childbearing potential agree to use appropriate method of contraception - Signed written informed consent
- - Extensive bone marrow fibrosis - Donor specific anti-HLA antibodies - Pregnancy - Medically unsuitable for transplant
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Khanh Nguyen
650-721-2372
View on ClinicalTrials.gov